Aspreva, Roche put CellCept on ice
Shares of Aspreva Pharmaceuticals slipped a bit this morning after the company and Roche announced that they would not be pushing ahead with a regulatory filing for CellCept, a new therapy for lupus nephritis. The therapy missed its late-stage primary endpoint--it was unable to demonstrate superiority to intravenous cyclophosphamide. There have been no new therapies approved for lupus in the U.S. in more than 40 years.
- check out the announcement
Related Articles:
Aspreva's CellCept fails late-stage superiority study. Report
Aspreva Pharmaceuticals drug fails Phase III trial. Report
CellCept wins orphan status. Report
Be the first to comment
More stories about Phase III lupus Roche Aspreva Pharmaceuticals Lupus Nephritis Orphan Status CellCept
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
